WellDoc®, a leading digital health company, announced today that its clinically proven hemoglobin A1C reductions for users of its BlueStar® digital therapeutic with type 2 diabetes can translate into significant healthcare cost savings.
{iframe}https://www.welldoc.com/images/uploads/WellDoc-Truven-Release.pdf{/iframe}